Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis‐generating perspective
Colorectal Disease · 2026-07 · 28 (7)
DOI: 10.1111/codi.70539 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Colorectal Disease, online erschienen am 03.07.2026. Verfasst von Mark Stratton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Hauptthemen laut MEDLINE: Lymph Node Excision, Colorectal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lymphadenectomy is traditionally central to curative colorectal cancer (CRC) surgery, with ≥ 12 retrieved lymph nodes being a well‐recognised quality indicator influencing staging and local control. However, contemporary immunology reframes tumour‐draining lymph nodes (TDLNs) as active co‐ordinators of anti‐tumour immunity.
Aim
This article examines whether routine lymphadenectomy may theoretically impair systemic immune surveillance and immune checkpoint inhibitor (ICI) response, a concern most applicable to mismatch repair‐deficient/microsatellite instability‐high (dMMR/MSI‐H) disease. Materials and Methods A review of surgical, oncological and immunological literature was performed, including comparison to breast cancer and melanoma, where sentinel lymph node biopsy (SLNB) and nodal preservation are standard.
Results
Retrospective CRC datasets demonstrate improved survival with increased nodal yield, though causality remains unproven and confounded by tumour biology, surgical quality and centre volume. Preclinical studies indicate TDLNs are essential for ongoing systemic immunity and optimal ICI effectiveness with early human data reporting improved outcomes with adjuvant immunotherapy. Evidence from breast cancer and melanoma provides indirect support for the concept of nodal preservation (SLNB ± observation) maintaining outcomes while reducing surgical morbidity, although lymphatic anatomy and systemic therapy differ from CRC.
Discussion
These concepts require further research to evaluate whether CRC surgical strategy in the immunotherapy era may need to balance oncological clearance against immune preservation. Selective nodal surgery guided by sentinel mapping or molecular tracers, integration with neoadjuvant and adjuvant immunotherapy trials, and molecular staging to reduce reliance on large nodal harvests represent key areas for investigation.
Conclusion
Prospective, stratified trials, especially in dMMR/MSI‐H vs. MSS cohorts, are needed to define when or if less may be more.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cambridge Colorectal Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
- Department of Surgery, University of Cambridge, Cambridge, UK.
ORCID-Profile: Mark Stratton, Justin Davies, Heman Joshi
Zitieren
APA
Stratton, M., Davies, J., & Joshi, H. (2026). Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis‐generating perspective. Colorectal Disease, 28(7). https://doi.org/10.1111/codi.70539
Vancouver
Stratton M, Davies J, Joshi H. Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis‐generating perspective. Colorectal Disease. 2026;28(7). doi:10.1111/codi.70539
BibTeX
@article{Stratton2026,
author = {Stratton, Mark and Davies, Justin and Joshi, Heman},
title = {Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis‐generating perspective},
journal = {Colorectal Disease},
year = {2026},
volume = {28},
number = {7},
doi = {10.1111/codi.70539}
}
EUVIMED